Ray Dalio’s Meridian Bioscience Inc VIVO Stock Holding History

Ray Dalio’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,827	Closed	-$1.69M	–	936
2022 Q4	$1.69M	Sell	50,827 -17,322	-25%	-$558K	0.01%	560
2022 Q3	$2.15M	Sell	68,149 -278	-0.4%	-$9K	0.01%	548
2022 Q2	$2.08M	Buy	68,427 +6,199	+10%	+$168K	0.01%	677
2022 Q1	$1.61M	Buy	62,228 +14,330	+30%	+$341K	0.01%	720
2021 Q4	$977K	Buy	47,898 +2,082	+5%	+$39.9K	0.01%	579
2021 Q3	$881K	Buy	45,816 +176	+0.4%	+$3.51K	﹤0.01%	537
2021 Q2	$1.01M	Buy	+45,640	New	+$968K	0.01%	585

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ray Dalio's VIVO Position: Q1 2023 in Review

Ray Dalio sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 50,827 shares — an estimated $1.69M sold.

Ray Dalio first reported a position in VIVO in Q2 2021 and held it in 7 quarters. The position peaked at $2.15M in Q3 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Ray Dalio reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Ray Dalio sold 50,827 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.69M.
Ray Dalio first reported a position in Meridian Bioscience Inc in Q2 2021 and held it in 7 quarters.
Ray Dalio's Meridian Bioscience Inc position peaked at $2.15M in Q3 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Bridgewater Associates's 13F filing for Q1 2023, filed 12 May 2023.